Relative bioavailability of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) administered with and without a spacer in healthy adults

P. Dorinsky (Durham, United States of America), P. Depetrillo (Baltimore, United States of America), K. Deangelis (Durham, United States of America), R. Trivedi (Durham, United States of America), M. Mo (Morristown, United States of America), S. Ballal (Morristown, United States of America), M. Gillen (Gaithersburg, United States of America)

Source: International Congress 2019 – COPD clinical studies: bronchodilators, corticosteroids and more
Session: COPD clinical studies: bronchodilators, corticosteroids and more
Session type: Poster Discussion
Number: 3376
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
P. Dorinsky (Durham, United States of America), P. Depetrillo (Baltimore, United States of America), K. Deangelis (Durham, United States of America), R. Trivedi (Durham, United States of America), M. Mo (Morristown, United States of America), S. Ballal (Morristown, United States of America), M. Gillen (Gaithersburg, United States of America). Relative bioavailability of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (BGF MDI) administered with and without a spacer in healthy adults. 3376

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Pharmacokinetics (PK) and safety of budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) and glycopyrronium/formoterol fumarate dihydrate (GFF) metered dose inhaler (MDI) in healthy Chinese adults
Source: International Congress 2018 – Pulmonary drug delivery: inhaler use, devices and technologies
Year: 2018


Pharmacokinetics (PK) of a single dose AZD7594 administered intravenously (IV), orally, and inhaled via two dry powder inhalers (DPI) and a pressurized metered-dose inhaler (pMDI)
Source: International Congress 2017 – Pulmonary drug and devices delivery
Year: 2017

Efficacy and safety of budesonide/formoterol fumarate dihydrate metered dose inhaler (BFF MDI) using co-suspension delivery technology compared to monocomponents and an active comparator in COPD
Source: International Congress 2018 – Pharmacological management of COPD
Year: 2018


Comparison of systemic pharmacodynamic effects of two HFA formulations of formoterol fumarate delivered by pressurised metered dose inhaler in healthy subjects
Source: Annual Congress 2009 - New aspects of inhalation therapy
Year: 2009

Assessment of relative potency of salbutamol administered via a metered-dose inhaler plus spacer or via a dry-powder inhaler in asthma patients
Source: Eur Respir J 2006; 28: Suppl. 50, 209s
Year: 2006

Comparability of formoterol dry powder (DPI) and metered dose inhalers (MDI) in asthma
Source: Eur Respir J 2005; 26: Suppl. 49, 50s
Year: 2005

Formoterol provides comparable bronchodilatation when delivered via dry powder (DPI) and metered dose inhalers (MDI) in adult asthma patients
Source: Eur Respir J 2005; 26: Suppl. 49, 339s
Year: 2005

Development of formoterol fumarate dihydrate powder for inhalation (6 µg and 12 µg per dose) delivered through a multi dose dry powder inhaler (MDPI)
Source: Eur Respir J 2004; 24: Suppl. 48, 582s
Year: 2004

Comparison of the efficacy and safety of ipratropium bromide (IB)/fenoterol hydrobromide (FEN) delivered by a new soft mist inhaler (SMI) or a conventional metered dose inhaler (MDI) in COPD patients
Source: Eur Respir J 2001; 18: Suppl. 33, 70s
Year: 2001

Efficacy and safety of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler (GFF MDI) delivered using co-suspension delivery technology in Japanese patients with moderate-to-very severe COPD
Source: International Congress 2018 – Pulmonary drug delivery: inhaler use, devices and technologies
Year: 2018


Asthma control with a breath-actuated pressurised metered dose inhaler (BAI) and prevalence of oral candidiasis: a prescribing claims study of 1701 patients prescribed a traditional pressurised metered dose inhaler (MDI) plus spacer or a BAI
Source: Eur Respir J 2002; 20: Suppl. 38, 78s
Year: 2002

Comparison of the efficacy and safety of ipratropium bromide (IB)/fenoterol hydrobromide (FEN) inhaled from a new soft mist inhaler (SMI) and from a conventional metered dose inhaler (MDI) in asthma patients
Source: Eur Respir J 2001; 18: Suppl. 33, 70s
Year: 2001

Clinical equivalence of salmeterol/fluticasone propionate combination 50/100mcg b.i.d. delivered via DiskusÔ or CFC-free metered dose Inhaler (MDI) in children with asthma
Source: Eur Respir J 2003; 22: Suppl. 45, 311s
Year: 2003

Bronchodilator response to salbutamol administered through metered-dose inhaler plus spacer or dry-powder inhaler in asthmatic patients
Source: Eur Respir J 2001; 18: Suppl. 33, 101s
Year: 2001

Efficacy and safety of two doses of budesonide/formoterol fumarate metered dose inhaler in COPD
Source: ERJ Open Res, 6 (2) 00187-2019; 10.1183/23120541.00187-2019
Year: 2020



Comparison of a dry powder inhaler (DPI) to a pressurized metered-dose inhaler (pMDI) formulation of extra fine beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/GB) in patients with COPD: The TRI-D study.
Source: Virtual Congress 2020 – COPD : inhaled corticosteroids, bronchodilators and eosinophils
Year: 2020


Relative pulmonary bioavailability (BA) of fluticasone propionate/formoterol (FP/FORM) via pressurised metered-dose inhaler (pMDI) and a novel breath-triggered inhaler (BTI)
Source: International Congress 2017 – Pulmonary drug and devices delivery
Year: 2017


A comparison of the efficacy of salmeterol/fluticasone propionate combination (SF) with beclometasone dipropionate (BDP) delivered via metered dose inhaler (MDI) in patients not well controlled on bronchodilators alone
Source: Eur Respir J 2001; 18: Suppl. 33, 53s
Year: 2001

Differences in patient perceived side effects (PPSE) of inhaled corticosteroids (ICS) between metered dose inhalers (MDI) and dry powder inhalers (DPI)
Source: Eur Respir J 2003; 22: Suppl. 45, 474s
Year: 2003

Comparison of proficiency of pressurized metered dose inhaler (pMDI) use with asthma control
Source: Annual Congress 2008 - Recent advances in the treatment and pathogenesis of asthma
Year: 2008